Zydus plans obesity jab launch in a novel pen device
Zydus plans obesity jab launch in a novel pen device is drawing significant interest across the industry.
Zydus has received regulatory approval from the Drug Controller General of India (DCGI) to market and manufacture semaglutide to treat type 2 diabetes and obesity.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Infosys pays average 85% performance bonus for Q3; payout to be credited with February salary
- Scientist and fitness icon Stephanie Buttermore passes away at 36
- What a Warner Bros-Paramount colossus would look like
- Panels on Jan Vishwas (Amendment of Provisions) Bill, Shiksha Adhishthan Bill get extensions to submit reports
Source: Original →